Samsung BioLogics shares rise after agrees to make Moderna COVID-19 vaccine
Shares in South Korean drug contract manufacturer Samsung BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna's COVID-19 vaccine. The agreement was part of Moderna Inc and Novavax Inc entering into a deal with the South Korean government to manufacture their COVID-19 vaccines.
View the full story here: https://www.reuters.com/business/healthcare-pharmaceuticals/samsung-biologics-shares-rise-after-agrees-make-moderna-covid-19-vaccine-2021-05-24/